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Available online 19 March 2020Human coronavirus, hCoV-19, is highly pathogenic with severe pneumonia associated with rapid virus replication.
Arising in Wuhan China December 2019, the current COVID-19 epidemic has rapidly grown with person-to-person in-
fection expanding to become a global health emergency now on pandemic scale.
Governments will not be able tominimise both deaths fromCOVID-19 and the economic impact of viral spread inmit-
igation of this current COVID-19 pandemic, according toAnderson et al. 2020 [1], Keepingmortality as low as possible
will be the highest priority for individuals; hence governments must put in placemeasures to ameliorate the inevitable
economic downturn. The current global picture shows small chains of transmission in many countries and large chains
resulting in extensive spread in a few countries, such as Italy, Iran, South Korea, and Japan.Most countries are likely to
have spread of COVID-19, at least in the early stages, before any mitigation measures have an impact. The scale of the
problem is massive. Here I consider new approaches to improve patient's biological resistance to COVID-19 using stem
cells, and how benefit might be scaled and simplified using synthetic stem cells to meet logistical needs within a short
time frame.Keywords:
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On the clinical front, the two key requirements in the COVID-19
pandemic are to reduce infection rate, and to decrease the death rate
of those infected. Whilst the majority of effort is aimed at infection,
there is also need for clinical research on how to best manage seriously
ill patients with COVID-19 [1]. Current available therapies - including
non-specific anti-virals, antibiotics to treat secondary bacterial infec-
tions and sepsis, and corticosteroids to reduce inflammation - fail in se-
vere disease where the hallmark is the cytokine storm induced by
COVID-19 in the lung, visible as inflammatory lesions with ground-
glass opacity on CT scan. Virally-triggered acute cytokine release of
IL-2, IL-6, IL-7, GSCF, IP10, MCP1, MIP1A and TNFα induces pulmo-
nary oedema, dysfunction of air-exchange, acute respiratory distress
syndrome, acute cardiac injury, and often secondary infection, leading
to death.
The Lancet has recently published the first comprehensive clinical
data on risk factors for COVID-19 mortality, with detailed clinical
course of illness including viral shedding that may continue in survi-
vors up to 37 days [2]. In-hospital death is associated with age and no-
tably IL-6 is a significant correlate. For COVID-19, the case fatality rate
(CFR) remains unknown until the number infected is determined, but
WHO estimates 0.3–1%, which is higher than 0.1% for influenza A.sevier B.V. This is an open access aThe accruing epidemiological analyses, linked with country-based mit-
igation strategies, and with estimates that about 80% COVID-19 pa-
tients have mild or asymptomatic disease, 14% severe disease, and
6% critically ill, underpin a continuing need for treatment of COVID-
19 pneumonia in the long term.
2. Mesenchymal stem cells
Two recent studies fromChina [3,4] have asked, canmesenchymal stem
cells (MSC) treat COVID-19 pneumonia, based on known immunomodula-
tory and reparative properties of stem cells? Both studies reveal remarkable
reversal of symptoms even in severe-critical conditions. Accordingly, these
clinical studies not only identify a novel therapeutic strategy, but also the
existence of natural mechanisms able to counteract acute inflammatory
pneumonia.
One study is a case report of a critically ill COVID-19 patient on a venti-
lator who had progressed despite intensive therapy, with markers showing
evidence of liver injury. This patient was treated with allogeneic human
umbilical cord MSC (hUCMSC) using three intravenous infusions of
5 × 107 hUCMSC, three days apart. Within four days of her second cell in-
fusion, the patient was off the ventilator and able to walk. All measured pa-
rameters, including circulating T cell counts, returned towards normal
levels – lymphocytes previously being low presumably due to sequestration
within the inflamed lungs and tissues. No obvious side effects were ob-
served [3].
The second study [4] was a pilot clinical trial to assess whether MSC
transplantation could improve the outcome of 7 enrolled patients withrticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
Fig. 1. Influence of endogenous LIF on responses to infection. Adapted from
Quinton et al. [6]. Previous Studies had shown that LIF is particularly important
for the epithelial STAT3 activating capacity of pneumonic alveolar lining, and
that treatment with exogenous LIF [9] or LIF over-expression [10] can limit
pulmonary inflammation in response to LPS or hyperoxia. The Quinton
experiment illustrated here investigates the requirement for endogenous LIF to
protect against acute lung injury. Lungs were collected from mice 24 h after
intratracheal inoculation of Escherichia coli co-instilled with anti-LIF or control
IgG. (A): Representative images of intact freshly isolated lungs and hematoxylin/
eosin-stained lung sections. Red circles denote infected left lung lobes. (B) Lung
wet:dry weight ratios show effect of anti-LIF treatment expressed as means ±
SEM. *p < 0.05 compared to mice treated with control IgG (n = 3–5). The anti-
LIF resulted in LIF being undetectable, whilst the other cytokines measured -
GCSF, GM-CSF, IL-10, IL-17, IL-1β, IL-6, KC, MIP-2 - were not significantly altered
by the anti-LIF treatment. (For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of this article.)
S.M. Metcalfe Medicine in Drug Discovery 5 (2020) 100019clinical COVID-19 pneumonia, with one critically severe, four severe,
and 2 non-severe. Before transplantation, all had high fever, shortness
of breath, and low oxygen saturation. Treatment was a single intrave-
nous dose of clinical grade MSCs, 1 × 106 cells per kilogram of weight.
Detailed follow-up over 14 days post-transplantation showed no ad-
verse effects, and within 2 days, all patients had significantly improved
pulmonary function, including the one severe COVID-19 pneumonia
case who was well enough for discharge by day 10. With full details
presented, overall, after treatment the peripheral lymphocytes in-
creased with a shift towards the regulatory phenotype for both CD4+
T cells and dendritic cells; and inflammatory cytokines significantly de-
creased whilst IL-10 increased.
The clinical MSC trial also asked if hCoV-19 infected the therapeutic
MSC cells. hCoV-19 enters cells through the ACE2 receptor widely dis-
tributed on human cells including alveolar and capillary endothelium.
The MSCs were ACE2 negative initially. During follow-up, using RNA-
seq survey to identify 12,500 transplanted MSC, it was revealed that
the cells had not differentiated and still remained ACE2 negative and
thus presumed free from COVID-19. Moreover, and remarkably, gene
expression profiles of the recovered MSC showed high anti-
inflammatory and trophic factor activity including TGFβ, HGF, LIF,
VEGF, EGF, BDNF and NGF, demonstrating that the immunomodula-
tory properties of the MSC are long-term and actively maintained by
continuing cytokine production.
However, whilst the MSC studies identify a new approach to treat
COVID-19 pneumonia, in practice the overwhelming scale of numbers of
patients needed to treat argue against cell therapy on logistical grounds.
What is the solution ? Here novel approaches to capture the therapeutic
properties of stem cells using nanotechnology become immediately
relevant.
3. Synthetic stem cells – “LIFNano”
LIF (leukaemia inhibitory factor) is known to be indispensable to
oppose the cytokine storm in the lungs during viral pneumonia
(Fig. 1) [5,6]. Although MSCs release LIF, as a solution this fails due
to being cell-based whilst carrying a prohibitive cost burden. Using
nanotechnology synthetic stem cells are available as “LIFNano” with
1000 times increase in potency compared to soluble LIF [7]. In EAE, a
preclinical model of Multiple Sclerosis (MS), treatment with LIFNano
treversed paralysis within 4 days (Fig. 2), a time line in accord with
that reported for beneficial effects in COVID-19 pneumonia using
MSC therapy. Previous studies using neural stem cells (NSC) to treat
EAE showed benefits that were solely dependent on NSC-derived LIF
[reviewed in 7]. As an emerging alternative to cell-based therapy,
such as LIFNano meet the need for a high volume and off-the-shelf ther-
apeutic agents able to rejuvenate damaged tissues and suppress cyto-
kine storm in pneumonia. Global distribution is simple using low
volume vials. Optional delivery routes include by inhalation or intrave-
nous or both.
4. Summary and urgency
Whilst new vaccines to reduce infection rate of COVID-19 are
being developed and scaled up, there is need to treat the significant
number of patients who develop pneumonia. The remarkable new
data using MSC demonstrate successful harnessing of natural endog-
enous pathways with powerful protective properties. With age,
growth factors associated with stemness decline in favour of more
inflammatory cytokines including IL-6 – a correlate with in-hospital
death resulting from COVID-19. But, for COVID-19 pneumonia, ther-
apy to remove inflammatory mediators - such as clearance by anti-
bodies - may fail to achieve the critcal balance between (i) the
endogenous anti-viral response and (ii) the controlling endogenous
protective and reparative action of LIF against excessive cytokine
storm.2Considering needs for mitigation of the current COVID-19 pan-
demic, with priority to keep mortality as low as possible, the finding
that MSC are safe and can reverse severe critical disease with high
potency is a major breakthrough representing an entirely new biolog-
ical approach to treatment that needs to be developed urgently.
To this end, stem cell biotech companies are joining forces
(e.g., Athersys and Mesoblast) [8], whilst the nanotechnology-based
synthetic stem cell LIFNano is ready for cGMP production at scale
today [7].
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LIFNano synthetic stem cell therapy 
EAE rapid reversal of paralysis 
SIGNIFICANCE 
- rapid recovery of motor function correlates with kinetics of myelin repair 
- LIFNano-CD4 crosses the Blood-Brain Barrier 
- Mice remain fully immune competent  
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Fig. 2. Paralysis in an EAE model is rapidly reversed by LIFNano therapy. C57/Bl10 mice were immunised against myelin protein (MOG) resulting in paralysis of hind limbs
and tail by day 14: protocol was the Hooke model of experimental allergic encephalopathy - this provides a standardised preclinical animal model of Multiple Sclerosis.
Untreated: Mice 15 days post immunisation showing paralysis of hind limbs and tail. Treated: Mice treated identically and showing paralysis at 15d, then followed by
4 days treatment with 1 mg/day i.p. LIFNano-CD4 nanoparticles. There is a significant recovery of movement: this improved further with prolonged therapy. The results
are highly reproducible, and control nanoparticles without LIF cargo targeted to CD4 had no effect on paralysis. (This study was part of an I-UK BMC Project “CELL-FREE
REGENERATIVE MEDICINE: Nano-Engineered “LIFNano” to treat Multiple Sclerosis” PROJECT NUMBER: 102847).
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